Suppr超能文献

在非洛地平亲水凝胶骨架缓释片药物释放试验中增溶剂的评价

Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine.

作者信息

Abrahamsson B, Johansson D, Torstensson A, Wingstrand K

机构信息

Pharmaceutical R&D, Astra Hässle, Mölndal, Sweden.

出版信息

Pharm Res. 1994 Aug;11(8):1093-7. doi: 10.1023/a:1018920412020.

Abstract

The drug release of felodipine, a water-insoluble drug, was tested by using sodium lauryl sulphate (SLS), polyoxyethylene 20 sorbitan monooleate (Tween) or cetyltrimethylammonium bromide (CTAB) in the test medium as solubilizers. Three slightly different felodipine extended-release (ER) tablets 10 mg based on the gel matrix principle were evaluated under different solubilizer concentrations, agitation intensities and pH. These tablets were also tested in a bioavailability study together with an oral solution. All three solubilizers substantially enhanced the drug solubility and sink conditions were obtained. The choice of solubilizer affected the drug release rate. This is most probably due to physico-chemical interactions between the gel-forming agent and the solubilizers. All in vitro test conditions provided a good correlation (r2 = 0.94-0.97) to in vivo dissolution, as determined by moment analysis. However, a much steeper in vitro/in vivo relationship was obtained for SLS compared to Tween and CTAB reflecting an inferior discrimination between the tablets by use of this anionic solubilizer.

摘要

以月桂醇硫酸酯钠(SLS)、聚氧乙烯20山梨醇酐单油酸酯(吐温)或十六烷基三甲基溴化铵(CTAB)作为增溶剂,在测试介质中对水不溶性药物非洛地平的药物释放进行了测试。基于凝胶骨架原理,对三种略有不同的10毫克非洛地平缓释片在不同增溶剂浓度、搅拌强度和pH值条件下进行了评估。这些片剂还与口服溶液一起进行了生物利用度研究测试。所有三种增溶剂均显著提高了药物溶解度,并达到了漏槽条件。增溶剂的选择影响药物释放速率。这很可能是由于凝胶形成剂与增溶剂之间的物理化学相互作用。通过矩量分析确定,所有体外测试条件与体内溶出均具有良好的相关性(r2 = 0.94 - 0.97)。然而,与吐温和CTAB相比,SLS的体外/体内关系更为陡峭,这反映出使用这种阴离子增溶剂时,片剂之间的区分能力较差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验